WCN23-0582 ECULIZUMAB FOR BEVACIZUMAB-INDUCED THROMBOTIC MICROANGIOPATHY

نویسندگان

چکیده

Bevacizumab-induced kidney side effects are common, mainly presented by blood hypertension (BH) and proteinuria (Pr), that generally resolve on drug withdrawal angiotensin-system blocker therapy. There is no standard threatment approach in cases of severe bevacizumab-induced injury associated with thrombotic microangiopathy (TMA). Eculizumab has been shown to be effective some these patients.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The use of eculizumab in gemcitabine induced thrombotic microangiopathy

BACKGROUND Thrombotic microangiopathy (TMA) secondary to gemcitabine therapy (GiTMA) is a very rare pathology that carries a poor prognosis, with nearly half of the cases progressing to end stage renal disease. GiTMA is most commonly associated with adenocarcinomas, most notably pancreatic cancers. The mainstay of management is withdrawal of the offending drug and supportive care. Plasmapheresi...

متن کامل

Progressive bevacizumab-associated renal thrombotic microangiopathy*

Vascular endothelial growth factor (VEGF) is integral to the integrity of the glomerular filtration barrier. Bevacizumab is a humanized monoclonal antibody directed against VEGF with expanding clinical applications for metastatic solid tumours. We describe a case of a 61-year-old female with ovarian cancer and baseline chronic kidney disease who received three doses of bevacizumab and subsequen...

متن کامل

Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report

BACKGROUND The incidence of gemcitabine-induced hemolytic uremic syndrome has already been described in adults. Several approaches have been employed in the treatment of gemcitabine-induced hemolytic uremic syndrome with different outcomes. One of the most promising agents is eculizumab, which is a monoclonal antibody directed against C5 complement protein. CASE PRESENTATION We reported the c...

متن کامل

Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab

BACKGROUND Interferon-beta (IFN-beta) is one of the most widely prescribed medications for relapsing-remitting multiple sclerosis (RRMS). IFN-related thrombotic microangiopathy (TMA) is a rare but severe complication, with a fulminant clinical onset and a possibly life-threatening outcome that may occur years after a well-tolerated treatment with IFN. Most patients evolve rapidly to advanced ch...

متن کامل

Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life‐saving treatment

Drug-induced aHUS is rare; however, early diagnosis is vital to reduce morbidity and mortality. With confirmation of the diagnosis, eculizumab appears to be a viable treatment option to suppress the pro-inflammatory surge. Furthermore, adverse side effects of medications such as carfilzomib and gemcitabine should be considered in the appropriate settings.

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Kidney International Reports

سال: 2023

ISSN: ['2468-0249']

DOI: https://doi.org/10.1016/j.ekir.2023.02.020